Remove clinical prep
article thumbnail

PrEP Initiation, Continuation Feasible in Range of Clinical Settings

Pharmacy Times

Wide-ranging options for HIV pre-exposure prophylaxis initiation in different settings and though different providers should be maintained to ensure underserved populations get adequate treatment options.

101
101
article thumbnail

Comparison Of Rebyota Versus Vowst: A Study Table To Help You Compare Fecal Microbiota Therapies

IDStewardship

rCDI is defined as clinically significant diarrhea and a positive test confirming CDI within eight weeks of completing treatment for CDI. diff treatment 24 to 72 hours after last dose of antibiotics 2 to 4 days after last dose of antibiotics Bowel prep required prior to therapy? Recommended Readings Peery AF, Kelly CR, Kao D, et al.

FDA 324
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Semi-Annual PrEP Dispensing with HIV Self-Testing Resulted in Continued Adherence After 12 Months

Pharmacy Times

Six-month preexposure prophylaxis (PrEP) dispensing supported by HIV self-testing resulted in PrEP adherence after 12 months and less visits to clinical sites.

122
122
article thumbnail

Research backs extended provision of ‘highly effective’ PrEP for HIV

Hospital Pharmacy Europe

HIV pre-exposure prophylaxis (PrEP) is highly effective at preventing HIV acquisition but greater provision is needed to meet the ‘large unmet need’ and maximise the potential of a national programme, say researchers who led a large trial of its use in England. It’s vital that all those who can benefit from PrEP can access it.

article thumbnail

Opinion: How to protect PrEP coverage, no matter what happens in Braidwood v. Becerra

STAT

Similar to earlier contraceptive mandate cases, Braidwood involves plaintiff-employers who object to paying for health insurance that includes coverage of disease screenings and PrEP for HIV on moral grounds. Their legal claims challenge the U.S. The decision was stayed by the 5th Circuit on May 15 pending its decision on appeal.

article thumbnail

Culturally Tailored Approaches Needed to Improve Access to PrEP for HIV

Pharmacy Times

Despite an increase in HIV and poorer clinical outcomes among migrant populations, the uptake of PrEP among these individuals has been understudied.

65
article thumbnail

Gilead wins court order against fraudsters targeting HIV programme

pharmaphorum

Gilead has won a crucial court order in a wide-ranging lawsuit against a network of clinics, prescribers, medical labs and pharmacies in Florida that it claims have been making fraudulent reimbursement claims for HIV medicines.